Zentiva Completes Voluntary Public Purchase Offer for APONTIS PHARMA AG

December 9, 2024

Zentiva has completed its voluntary public purchase offer for the shares of APONTIS PHARMA AG. Following settlement, Zentiva holds approximately 83.57% of the share capital and approximately 85.27% of the voting rights, with management agreeing to terminate the shares’ inclusion in trading on the Freiverkehr immediately after settlement.

Buyers
Zentiva AG
Targets
APONTIS PHARMA AG
Platforms
Zentiva AG
Industry
Pharmaceuticals
Location
Germany
Transaction Type
Buyout

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.